Mayo Clinic Licenses Expression Pathology Technology for MS-based Amyloidosis Assay

Mayo applied the technology for solubilizing and capturing the protein content in FFPE tissue to develop a mass spectrometry-based method for the diagnosis and classification of amyloidosis in routine biopsy samples in a clinical setting. It will offer its test through its reference lab.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.